DMKPQ (DMK Pharmaceuticals) Short Percentage of Float


DMKPQ DMK Pharmaceuticals Corp DMKPQ
16 GF Score
Price $0.00
View Full Analysis

What is DMK Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

DMKPQ vs CNNC, THCT, VFRM: Short Percentage of Float Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DMK Pharmaceuticals Short Percentage of Float vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where DMK Pharmaceuticals's Short Percentage of Float falls into.


DMKPQ
16GF Score
DMK Pharmaceuticals Corp DMKPQ
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DMK Pharmaceuticals Business Description

Address 11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
16GF Score

Get the complete analysis for DMKPQ

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price